Mo et al. reported that the overexpression of tRF-17-79MP9PP in breast cancer cells weakened thrombospondin-1-mediated TGF-β1/SMAD3 signaling, suggesting that it may be a potential therapeutic target for breast cancer [19]. Here, SMAD3 is linked to breast cancer.